Dr. Wedam is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8901 Wisconsin Ave
Bldg 8, Rm 5101
Bethesda, MD 20889Phone+1 301-496-0901Fax+1 301-496-0047
Education & Training
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1997 - 2001
Georgetown University School of MedicineClass of 1997
Certifications & Licensure
VA State Medical License 1998 - 2026
DC State Medical License 1999 - 2000- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer Start of enrollment: 2001 May 13
- Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer Start of enrollment: 2003 Nov 01
Publications & Presentations
PubMed
- 4 citationsMeasuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statement.Wanda Cui, Rodney P Rocconi, Ramya Thota, Richard A Anderson, Suanna S Bruinooge
The Lancet. Oncology. 2023-10-01 - 30 citationsU.S. FDA Drug Approvals for Breast Cancer - A Decade in Review.Shaily Arora, Preeti Narayan, Christy Osgood, Suparna Wedam, Tatiana M. Prowell
Clinical Cancer Research. 2021-10-28 - 4 citationsU.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review.Shaily Arora, Shaily Arora, Preeti Narayan, Preeti Narayan, Gwynn Ison
Clinical Cancer Research. 2021-10-28
Press Mentions
Inavolisib FDA-Approved for Triplet Combination Use for Metastatic Breast CancerJanuary 7th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
